Search

Displaying results 7361 - 7370 of 10000 in total
  1. Drug

    Livoletide

    go.drugbank.com/drugs/DB15188
    Investigational

    Livoletide is under investigation in clinical trial NCT03790865 (Effects of Livoletide (AZP-531) on Food-related Behaviors in Patients With Prader-Willi Syndrome).

  2. Drug

    Bixalomer

    go.drugbank.com/drugs/DB15200
    Investigational

    Bixalomer is under investigation in clinical trial NCT01115985 (A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Atorvastatin in Healthy Volunteers).

  3. Drug

    Ethylestrenol

    go.drugbank.com/drugs/DB01493
    ApprovedWithdrawn

    An anabolic steroid with some progestational activity and little androgenic effect. [PubChem]

  4. Drug

    GC5107

    go.drugbank.com/drugs/DB17604
    Investigational

    GC5107 is an investigational intravenous immunoglobulin. It is marketed as IVIG-SN.

  5. Drug

    Gaxilose

    go.drugbank.com/drugs/DB12767
    ApprovedWithdrawn

    Gaxilose has been used in trials studying the diagnostic of Lactose Intolerance.

  6. Drug

    Parethoxycaine

    go.drugbank.com/drugs/DB19380
    ApprovedWithdrawn

    Parethoxycaine is a local anesthetic that was previously approved in the US.

  7. Drug

    Tyrosol

    go.drugbank.com/drugs/DB16855
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Eosin

    go.drugbank.com/drugs/DB13706
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Sea salt

    go.drugbank.com/drugs/DB11266
    Approved

    Unlike sea salt, table salt usually contains an additive to prevent clumping and involves addition of iodine. … In comparison, table salt is mined from underground sedimentary deposits and is more heavily processed to eliminate minerals.

    Products: Ruby Cell 4u Mud Moisture Pure, S Panax All In One Liquidsoap
  10. Drug

    Emicizumab

    go.drugbank.com/drugs/DB13923
    ApprovedInvestigational

    Emicizumab was originated as an improved form of hBS23 and it was approved on November 16, 2017.[A31279, L1016] It was created by Chugai Pharmaceuticals Co.